Thus, the inhibition of SUMOylation should be explored as a therapeutic option for treatment of MYC-dependent B-cell lymphomas and NPM-ALK+ T-cell lymphomas. This evidence concerns the gene ALK and T-cell non-Hodgkin lymphoma.